SINTX Technologies has partnered with NED Medical to develop advanced ceramic-based microspheres for radiotherapeutic applications.
The collaboration between SINTX Technologies and NED Medical aims to expedite the transition of microsphere production from research and development to pilot production.
SINTX Technologies has demonstrated its capability to produce ceramic-based microspheres containing the Yttrium-90 radioisotope, which are intended for use in transarterial radioembolization devices for treating liver cancer.
The microspheres feature porosity that allows for future adaptations in targeted chemotherapy and combination therapies.
The partnership between SINTX Technologies and NED Medical is expected to yield next-generation radiotherapeutic solutions that could significantly impact cancer treatment.
SINTX's advanced ceramic processing has been instrumental in developing CombiSphere, a next-generation radio-labeled microsphere with differentiated properties.
The partnership marks a strategic expansion for SINTX Technologies into the high-growth field of radio therapeutics.
It also lays the groundwork for future collaborations, including scaling production, further testing, and exploring expanded indications within oncology and musculoskeletal applications.
SINTX Technologies aims to unlock new revenue opportunities through this partnership and strengthen its foothold in the medical device market.
The implications for both companies and the broader medical community could be profound, paving the way for innovative solutions in the fight against cancer.